https://www.biospace.com/biondvax-announces-rights-offering-in-support-of-ongoing-pivotal-clinical-efficacy-phase-3-trial-of-the-m-001-universal-flu-vaccine-and-scale-up-of-manufacturing-process
BiondVax Announces Rights Offering in Support of Ongoing Pivotal, Clinical Efficacy Phase 3 Trial...
Jun 10, 2019 - The Company anticipates results of the Phase 3 trial will be announced by the end of 2020.
https://www.ig.com/nl/aandelen/markten-aandelen/biondvax-pharmaceuticals-limited
Koers BiondVax Pharmaceuticals Limited | Aandeel BiondVax Pharmaceuticals Limited | BiondVax...
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally... [NL]
koersbiondvaxpharmaceuticalslimitedaandeel
https://www.eib.org/en/projects/all/20150572
BIONDVAX UNIVERSAL FLU VACCINE (IDFF)
Contingent risk sharing loan for the research and development of a new vaccine against flu pandemic.
universal flu vaccinebiondvax
https://www.biospace.com/biondvax-to-provide-update-of-m-001-universal-flu-vaccine-pivotal-phase-3-clinical-trial-at-18th-mixiii-biomed-conference
BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at 18th...
May 14, 2019 - BiondVax Pharmaceuticals Ltd., developer of the M-001 universal influenza vaccine candidate, reported it will present this week at the 18th MIXiii-BIOMED...
https://www.biospace.com/biondvax-announces-pricing-of-9-0-million-follow-on-underwritten-offering-of-american-depositary-shares
BiondVax Announces Pricing of $9.0 million Follow-on Underwritten Offering of American Depositary...
Dec 27, 2021 - BiondVax Pharmaceuticals Ltd. today announced the pricing of an underwritten public offering of 3,813,560 American Depositary Shares.
https://www.eib.org/de/projects/all/20150572
BIONDVAX UNIVERSAL FLU VACCINE (IDFF)
Contingent risk sharing loan for the research and development of a new vaccine against flu pandemic.
universal flu vaccinebiondvax
https://www.prnewswire.com/news-releases/biondvax-announces-second-quarter-2021-financial-results-and-provides-business-update-301363895.html
BiondVax Announces Second Quarter 2021 Financial Results and Provides Business Update
/PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing...
second quarter2021 financialbiondvaxannounces